Rehyde Health Solutions is establishing Thailand's premier natural-extraction psilocybin API manufacturing facility — purpose-built for the global research and clinical pipeline.
Rehyde Health Solutions Co., Ltd. is a Thailand-registered biotech company developing a natural-extraction psilocybin Active Pharmaceutical Ingredient (API) manufacturing facility to serve the growing global clinical and research market.
We are currently in the process of establishing our operations in close coordination with the relevant Thai authorities — including the Thai FDA, the Office of Narcotics Control Board (ONCB), and strategic institutional partners — to secure the necessary narcotics manufacturing licenses and GMP certifications required for pharmaceutical-grade production and international export.
Our facility design leverages Thailand's progressive April 2024 regulatory framework, which explicitly permits psilocybin mushroom cultivation for medical and research purposes, making Thailand one of only a handful of jurisdictions globally where a compliant manufacturing pathway exists.
Every aspect of our facility design prioritizes full regulatory compliance — from ONCB security standards to Thai FDA narcotics manufacturing requirements and international GMP certification.
Our ethanol/water extraction and Centrifugal Partition Chromatography (CPC) purification process delivers pharmaceutical-grade purity while maintaining the provenance of natural-source psilocybin.
Purpose-built to supply international markets including clinical trial sponsors, research institutions, and licensed treatment providers in jurisdictions with established access frameworks.
Our phased development strategy is designed to have a fully GMP-certified, production-ready facility operational in time for the anticipated expansion in global demand.
Engaging Thai FDA and ONCB for narcotics manufacturing license (Form YS-5) applications. Coordinating with institutional partners on facility site preparation and security compliance requirements.
Establishing international regulatory relationships for future export permit facilitation with destination country authorities.
In ProgressLab-scale extraction to produce initial sample material for customer qualification and analytical method validation. Establishing quality control laboratory and Certificate of Analysis capabilities.
Target output: qualification-grade material for prospective partner evaluation.
UpcomingFull GMP certification of extraction and purification facility. Commissioning of controlled-environment agricultural cultivation infrastructure with HEPA filtration and environmental monitoring.
Scaling production capacity in line with secured offtake agreements and market demand signals.
PlannedExpansion of production capacity to meet growing post-approval clinical demand. Broadening export partnerships across multiple jurisdictions as regulatory access programs expand globally.
2027–2028A unique convergence of regulatory, economic, and strategic factors positions Rehyde Health at the forefront of pharmaceutical psilocybin supply.
Thailand's April 2024 ministerial notification explicitly permits psilocybin mushroom cultivation for medical and research purposes — the first and only such framework in Asia. This provides a clear, legal manufacturing pathway unavailable anywhere else in the region.
Thailand's pharmaceutical manufacturing cost structure is substantially lower than comparable facilities in Canada or Western Europe, enabling competitive pricing without compromising quality or compliance standards.
Our facility development benefits from partnerships with Thai institutional stakeholders that provide operational support, site infrastructure, and alignment with Thailand's national health research priorities.
As the market evolves, natural-derived psilocybin is emerging as a preferred API source for clinical trial sponsors and treatment providers seeking differentiation from synthetic alternatives.
As an export-oriented biotech manufacturer, Rehyde qualifies for Thailand Board of Investment incentive schemes including potential corporate tax exemptions and import duty waivers on production equipment.
With major Phase 3 clinical programs advancing toward regulatory submissions, the global psilocybin API market is poised for substantial growth. Rehyde is building to be production-ready at the inflection point.
Our manufacturing process follows established pharmaceutical extraction and purification methodologies validated in peer-reviewed literature and commercial production.
HEPA-filtered, climate-controlled cultivation infrastructure with continuous environmental monitoring, ensuring consistent biomass quality and psilocybin content batch-to-batch.
Optimized polar extraction methodology using 60–80% ethanol/water at ambient temperature — the scientifically validated approach for the highly polar psilocybin molecule (C₁₂H₁₇N₂O₄P).
Centrifugal Partition Chromatography using industry-standard Rousselet Robatel equipment, achieving 95–99% purity with 85–95% recovery rates. No column packing degradation — consistent performance over time.
Full analytical QC laboratory with HPLC quantification, batch-specific Certificates of Analysis, stability testing protocols, and complete traceability documentation for regulatory submissions.
We're actively engaging with clinical trial sponsors, research institutions, and licensed treatment providers seeking a reliable, GMP-compliant psilocybin API supply partner.
[email protected]